Which medication is NOT a first-line therapy for hepatitis B?

Which medication is NOT a first-line therapy for hepatitis B?

• A. Pegylated interferon
• B. Entecavir
• C. Tenofovir
• D. Ribavirin

Answer: (D)

Treating chronic hepatitis B aims to suppress viral replication with agents that have a strong, durable effect and a low risk of resistance, while also considering safety and treatment duration. Ribavirin does not provide sustained HBV suppression and has little to no activity against hepatitis B when used alone, so it is not recommended as first-line therapy. Its main role is in other infections (notably HCV) or in specific coinfection scenarios, but not as the standard initial treatment for HBV. In contrast, entecavir and tenofovir are potent nucleos(t)ide analogs with high barriers to resistance and strong antiviral efficacy, making them common first-line choices. Pegylated interferon is another option in select patients, offering a finite treatment duration and potential for seroconversion, though responses vary.

Treating chronic hepatitis B aims to suppress viral replication with agents that have a strong, durable effect and a low risk of resistance, while also considering safety and treatment duration. Ribavirin does not provide sustained HBV suppression and has little to no activity against hepatitis B when used alone, so it is not recommended as first-line therapy. Its main role is in other infections (notably HCV) or in specific coinfection scenarios, but not as the standard initial treatment for HBV.

In contrast, entecavir and tenofovir are potent nucleos(t)ide analogs with high barriers to resistance and strong antiviral efficacy, making them common first-line choices. Pegylated interferon is another option in select patients, offering a finite treatment duration and potential for seroconversion, though responses vary.